$heff's $tation of $tocks & $olid DD

[barefootrunner]

DEPO - Solid Investment with a Short Term Catalyst

I traded DEPO earlier this year after the overreaction to XNPT's CRL sent shares below $2.50. Since then, DEPO has continued to impress and now has a forward looking event in January 2011 that could significantly increase shareholder value - the PDUFA for DM-1796 - extended release, once-daily, gabapentin tablets for pain associated with post-herpetic neuralgia (PHN). The date is 1/30/2011.

While this is a solid future catalyst, DEPO has proven that it is a great longer-term investment by continuing to drive shareholder value. With a market cap of $277mm, two marketed products and a recent, profitable Q3, DEPO is catching the eye of value investors.

I am still looking into the market potential for DM-1796, but below is some of the recent news out of DEPO as well as links to their pipeline / and AcuForm delivery technology:

Pipeline

http://www.depomedinc.com/view.cfm/1285/Our-Pipeline

AcuForm Delivery Technology

http://www.depomedinc.com/view.cfm/32/Our-Technology

UPDATE 1-Depomed posts surprise Q3 profit

http://www.reuters.com/article/idCNSGE6A00M320101101?rpc=44

Depomed Receives $2.5 Million Milestone Payment Under Merck License Agreement

http://finance.yahoo.com/news/Depomed-Receives-25-Million-iw-415026398.html?x=0&.v=1

Depomed Reaches SPA Agreement With FDA for Phase 3 Hot Flash Trial

http://www.streetinsider.com/Press+Releases/Depomed+Reaches+SPA+Agreement+With+FDA+for+Phase+3+Hot+Flash+Trial/5885116.html

The Michael J. Fox Foundation Awards Depomed a Second Development Grant in Parkinson's Disease

http://finance.yahoo.com/news/The-Michael-J-Fox-Foundation-iw-4187896534.html?x=0&.v=1